Overview

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Bradykinin
Icatibant